Atsena Therapeutics – Press Releases

November 7, 2022

Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer

Biotech leader brings extensive experience in finance, business development and corporate strategy DURHAM, NC, November 7, 2022 – Atsena Therapeutics, a clinical-stage gene therapy company ...

October 3, 2022

Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)

ATSN-101 demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events Data presented at the American Academy of Ophthalmology 2022 Annual Meeting DURHAM, ...

October 1, 2022

Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)

View the AAO presentation.

September 21, 2022

Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting

Data from Phase I/II trial of ATSN-101 in patients with GUCY2D-associated Leber congenital amaurosis (LCA1) to be presented DURHAM, NC – Atsena Therapeutics, a clinical-stage gene ...

July 27, 2022

Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle

World-class facility supports the company’s growth, and discovery and development of gene therapies for inherited retinal diseases DURHAM, NC – Atsena Therapeutics, a clinical-stage gene ...

May 2, 2022

Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting

Presentations to feature laterally spreading capsid for the treatment of X-linked retinoschisis and dual vector technology for the treatment of MYO7A-associated Usher syndrome DURHAM, NC ...

October 18, 2021

Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids

Subretinal delivery of RS1 using AAV capsid that spreads laterally beyond the injection site overcomes challenges associated with intravitreal delivery DURHAM, NC – Atsena Therapeutics, a ...

August 16, 2021

Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer

Dr. Couto strengthens leadership team with extensive AAV and ocular gene therapy expertise DURHAM, NC – Atsena Therapeutics, a clinical-stage gene therapy company focused on ...

July 12, 2021

Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors

DURHAM, NC – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today ...

June 28, 2021

Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1

Phase I/II clinical trial is ongoing in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D DURHAM, NC – Atsena Therapeutics, a clinical-stage ...

June 14, 2021

Atsena Therapeutics Appoints Kenji Fujita, MD, as Chief Medical Officer

Dr. Fujita brings extensive clinical development and regulatory strategy experience DURHAM, NC – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing ...

December 16, 2020

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases

Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors Company expands board of directors and plans to build ...

July 29, 2020

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis

Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the ...